Cristina Guarducci

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New study examining pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer now published in
@Nature_NPJ #BreastCancer.
👉https://t.co/CeJA7kfbdw
@AlbertGrinshpun @RMJesel @nlinmd @SKabrajiMD @gkirkner @CriGuarducci @SantagataLab

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New📰| Selective #CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive #BreastCancer | Full text in @CCR_AACR. @CriGuarducci @RMJesel @GShapiroMDPhD @AlbertGrinshpun
➡️https://t.co/PxIBLa7gyd

[Luca Malorni @LMalorni]

Just published ‼️our latest report on the ctDNA mutational analysis within the TREnd trial exploring palbociclib alone or in combo with ET in metatstatic breast cancer https://t.co/AB9ibL5VW7 @AIRC_it @curijoey @CarmenCriscit @CriGuarducci @laura_biga @benelli_matteo

[Dana-Farber Data Science @dfcidatascience]

Svitlana Tyekucheva, PhD leads statistical collaboration for PYTHIA, a phase II global trial evaluating #genomics & progression free survival for post-menopausal women with advanced #breastcancer whose disease progressed after hormone therapy: https://t.co/cdcX6gdtuv @etop_ibcsg

[Sara Tolaney @stolaney1]

Beautiful discussion by @shomgoel

NF1 loss assoc 2/endocrine resistance
NF1 low/mutant tumors more sensitive to cdk 4/6i
NF1 loss leads to ⬆️phosphorylation of cdk4 + Rb

Functional loss of NF1 may be more common in ER+ BC than previously thought.

@OncoAlert #SABCS23

[Erica Mayer @elmayermd]

Rinath Jeselsohn from @DFCI_BreastOnc presenting sophisticated analysis of BL and serial ctDNA from PACE trial, elucidating mechanisms of resistance to ET and CDK4/6i. And moderated by Ada Waks! #SABCS23 @DanaFarber

[SABCS @SABCSSanAntonio]

.@CharlesSwanton discussed "Breast cancer evolution, immune evasion, and metastasis driven by chromosomal instability" during his plenary lecture this afternoon at #SABCS23.
@UTHealthSAMDA @AACR

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New📰Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive #breastcancer published in @CR_AACR.
@RMJesel @Otto_DFCI @stolaney1 @EMittendorfMD @NabihahTayob
Fulltext here: https://t.co/tOjjLUojBv

[Oncologia Prato @OncologiaPrato]

Please join @NardoneAgostina at the poster session presenting “AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance” #ESMOBreast23

[Susan G. Komen @SusanGKomen]

Susan G. Komen is excited to announce that nine world-renowned breast cancer researchers will join the organization as Komen Scholars to help guide Komen’s work so that people who have been diagnosed with breast cancer can live longer, better lives. https://t.co/umHTC1CIMi

[Oncologia Prato @OncologiaPrato]

Biomarkers of response and resistance - @LMalorni @OncologiaPrato #SABCS22

[Cristina Guarducci @CriGuarducci]

Great job!👏👏👏

[Oncologia Prato @OncologiaPrato]

@OncologiaPrato at #SABCS22 @LMalorni @EmanuelaRisi85 and Amelia McCartney

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

The @SABCS22 Meeting News write-up, "Osborne Symposium highlights growing understanding of HER2, ER crosstalk" featured comments from Dr. Rinath Jeselsohn's @RMJesel talk. Read the full article here: https://t.co/HHIDgp2abq

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Dr. Rinath Jeselsohn (@RMJesel) and colleagues published a new study examining how a "A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular #BreastCancer." #bcsm https://t.co/FCHPPfU0hS

[ESMO - Eur. Oncology @myESMO]

With great sadness we join the oncology community in mourning the passing of Angelo Di Leo, a giant in the #breastcancer field and recipient of the ESMO Lifetime Achievement Award in 2019 and member of the @Annals_Oncology Editorial Board. Our thoughts are with his loved ones.

[Total Health™ @TotalHealthConf]

Tomorrow is the @KUcancercenter Post San Antonio Review! Our expert speakers have lots of innovation and highlights from #SABCS to share with you. Register free: https://t.co/X5MFK5suRN #BCSM

[Cristina Guarducci @CriGuarducci]

@CasaLettori @FaziEditore Sfortunatamente sono un'altra Cristina Guarducci. Non sono la scrittrice...

[Cristina Guarducci @CriGuarducci]

@merimeddy @CasaLettori @FaziEditore Sfortunatamente non sono la Cristina Guarducci che pensava di menzionare. Io sono una sua omonima. Mi occupo di tutt'altro. Ma credo che dovrò iniziare a leggere i romanzi dell'altra Cristina Guarducci!

[Cristina Guarducci @CriGuarducci]

@lucignolo ma almeno si preoccupano di quali farmaci gli vengono somministrati e dei relativi effetti collaterali?